1. Introduction
===============

Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease that mainly impacts the axial skeleton, peripheral joints, and others.^\[[@R1]--[@R3]\]^ It manifests with the back pain, loss of spinal mobility, joint stiffness, and fatigue.^\[[@R4],[@R5]\]^ If such condition cannot be treated effectively and timely, it may result in spinal deformity and ankylosis.^\[[@R6]\]^ It has been reported that its prevalence ranges from 0.5% to 1.6%, and such condition occurred more commonly in men than women.^\[[@R7],[@R8]\]^

The availability of treatment options are still limited for AS. Although several medications are utilized to treat this condition, their efficacy is still not satisfied, and lots of adverse events are accompanied after long term taken.^\[[@R2],[@R9]--[@R12]\]^ Thus, alternative therapy is urgently needed to treat this condition.

Complementary and alternative therapy (CAT) is a potential candidate to treat AS.^\[[@R13],[@R14]\]^ It has been reported that CAT intervention may benefit for patients with AS.^\[[@R13],[@R14]\]^ Such intervention mainly consists of acupuncture, moxibustion, Chinese herbal medicine, ultrasound therapy, physical therapy, and transcutaneous electrical nerve stimulation (TENS).^\[[@R15]--[@R24]\]^ Of these, TENS is reported to treat patients with AS effectively. However, limited data are still available concerning its effect patients with chronic pain after AS. Therefore, in this retrospective study, we explored the effect of TENS in patients with chronic pain following AS.

2. Methods
==========

2.1. Ethics
-----------

This study was approved by the Ethical Committee of the Fourth People\'s Hospital of Shaanxi. Written informed consent was required from each patient.

2.2. Design
-----------

The present study was a retrospective study, and 72 patients with chronic pain following AS were assigned to a treatment group and a control group equally. The data was collected during March 2016 to November 2017 in the Fourth People\'s Hospital of Shaanxi. The patients in the treatment group received exercise plus TENS therapy, while the subjects in the control group received exercise only. All outcome measurements were evaluated before and after 6 week treatment.

2.3. Patients
-------------

In this study, a total of 72 eligible patients with the confirmed diagnosis of chronic pain after AS were included, based on the modified New York criteria for AS.^\[[@R25]\]^ All patients suffered from chronic spinal pain more than 6 months before this study, measured by score on the visual analog scale (VAS; 0--10 scale) ≥ 4. All patients aged from 23 to 75 years old. The cases were excluded if the patients had severe organ diseases, administered corticosteroids, joint injections, exercise, or TENS in the past 1 month. In addition, the case was also excluded if it had incomplete information.

2.4. Intervention
-----------------

Patients in both groups received exercise.^\[[@R26]\]^ This intervention consisted of postural exercises and analytic flexibility exercises. All the exercises worked at the cervical, thoracic, and lumbar spine. Moreover, this schedule also included the stretching of the erector spinae, hamstrings, and shoulder muscles, as well as the exercises of chest expansion, and breathing.

In addition, patients in the treatment group also underwent TENS therapy. It was applied by TENS stimulator device to the painful area TENS stimulator (ENS 931; Enraf Nonius, Rotterdam, South Holland, the Netherlands) with 2 electrodes. It delivered frequency of 100 Hz, pulse duration of 100 μs for 30 minutes each time. The current intensity was gradually increased to the maximum tolerance of individuals. It was performed 2 times weekly for a total of 6 weeks.

2.5. Outcomes
-------------

The primary outcome was pain intensity. It was assessed by the VAS, ranges from 0, no pain, to 10, severest pain.^\[[@R27]\]^ The secondary outcomes consisted of degree of functional limitation, measured by Bath Ankylosing Spondylitis Functional Index (BASFI), varies from 0 to 10, with higher score indicating heavier functional limitation;^\[[@R28]\]^ and quality of life, measured by Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire, ranges from 0 to 18, with higher score indicating worse quality of life.^\[[@R29]\]^ In addition, adverse events were also documented. All the outcomes measurements were assessed before and after 6 weeks treatment.

2.6. Statistical analysis
-------------------------

All data were analyzed by the statistician using SPSS software (SPSS V.17.0, IBM Corp., Armonk, NY). Chi-square test was applied to analyze the categorical data, while *t* test or Mann--Whitney *U* test were utilized to analyze the continuous data. The statistical significance level was defined as *P* \< .05.

3. Results
==========

In this retrospective study, all characteristics of subjects in both groups were demonstrated in Table [1](#T1){ref-type="table"}. The comparison of all those characteristics did not differ significantly between 2 groups. The characteristics included age, sex, race, marital status, body mass index, disease duration, and previous medication (Table [1](#T1){ref-type="table"}).

###### 

Patients demographics and characteristics.
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After 6-week treatment, patients in the treatment group did not show better outcomes in reduction of pain intensity, as measured by VAS (*P* = .08, Table [2](#T2){ref-type="table"}); functional improvement, as assessed by BASFI (*P* = .19, Table [3](#T3){ref-type="table"}); and enhancement of quality of life, as evaluated by ASQoL (*P* = .18, Table [4](#T4){ref-type="table"}), compared those patients in the control group.

###### 

Comparison of pain intensity pre/post treatment.
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###### 

Comparison of degree of functional limitation pre/post treatment.
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###### 

Comparison of quality of life pre/post treatment.
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No adverse events were recorded in this study. No death related to the treatment occurred in both groups.

4. Discussion
=============

Two previous published studies addressed investigating the efficacy of TENS for the treatment of patients with AS.^\[[@R23],[@R24]\]^ They found that TENS is significantly better than placebo in treating lumbar pain and stiffness following AS.^\[[@R23],[@R24]\]^ Although their results were still insufficient statistically significance, it was recommended to lower the analgesic medications.

The results of this retrospective study are inconsistent with the previous study.^\[[@R23],[@R24]\]^ This study found that patients in the treatment group did not exert greater effectiveness in chronic pain relief, measured by VAS, compared with patients in the control group. In addition, patients received TNES also did not enhance the degree of functional limitation, measured by BASFI; and failed to improve the quality of life, measured by ASQoL questionnaire. However, no adverse events occurred in both groups. The results of this study indicated that TENS may not benefit for patients with chronic pain, and quality of life caused by AS after 6-week treatment.

This study has several limitations: first, the dose of this study may be insufficient for the chronic pain relief following AS, because it only utilized TENS twice weekly for a total of 6 weeks. Second, the sample size of this retrospective is quite small, which may impact the effectiveness evaluation of TENS for chronic pain after AS. Third, the current study may consist of incomprehensive outcome assessments, due to the only available data of this retrospective study.

5. Conclusion
=============

The results of this study did not exert that TENS may benefit for patients with chronic pain following AS after 6-week treatment.
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